腹腔热灌注化疗在中晚期上皮性卵巢癌患者中的应用

Application of hyperthermic intraperitoneal chemotherapy in patients with middle-advanced epithelial ovarian cancer

目的观察腹腔热灌注化疗中晚期上皮性卵巢癌中的临床疗效。方法选取2014年10月~2017年10月期间在阳江市人民医院妇科住院的32例中晚期(Ⅱ~Ⅳ期)上皮性卵巢癌患者作为研究对象,随机分为两组(治疗组和对照组)。两组都行肿瘤细胞减灭术,治疗组术后行腹腔热灌注化疗3次后再常规行静脉化疗,对照组则行单纯静脉化疗。术后每3个月常规复查一次,了解患者的CA125、HE4及影像学检查是否出现新的病灶,分析两组患者的疾病有效率及不良反应发生率。结果治疗组的有效率为88.2%,不良反应发生率为22%;对照组的有效率为66.6%,不良反应发生率为21.8%。结论腹腔热灌注化疗可提高中晚期卵巢癌患者的无进展生存率,且不良反应无明显增加。

Objective To observe the clinical efficacy of hyperthermic intraperitoneal chemotherapy（HIPEC） in patients with middle-advanced epithelial ovarian cancer. Methods From October 2014 to October 2017, Thirty two cases with middle-advanced epithelial ovarian cancer（Stage Ⅱ to Ⅳ） who treated in Department of Gynecology of the People’s Hospital of Yangjiang City were performed cytoreductive theraphy and selected, and were divided into control group and observation group. The patients in the observation group（n=17） received HIPEC 3 times after the operation, followed by routine intravenous chemotherapy. The patients in control group（n=15） were treated with intravenous chemotherapy. Both of the two groups were reviewed for three months. The CA125, HE4, imaging, effective rate and side effects of two groups were conpared. Results The effective rate of observation group was 88.2%,the side effects rate was 22%. The effective rate of control group was 60%,the side effects rate was 21.8%. Conclusion HIPEC can improve the progression free survival rate of middle-advanced epithelial ovarian cancer. And the side effects rate isn’t increased.